Concepedia

Author

Frederick Millard

University of California San DiegoORCID

Also Known As

F Millard, F. E. Millard, F. Millard, Frederick E. Millard, Frederick Millard

75

Publications

2K

Citations

21

H-Index

41

Concepts

All Affiliations

University of California San DiegoDana-Farber Cancer InstituteMemorial Sloan Kettering Cancer CenterNaval Medical Center San DiegoUniversity of California, San Francisco
FM

About

Frederick Millard is an author at University of California San Diego specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

12

12

801

2

Health Sciences

2

2

74

3

Education

1

1

292

4

Family Medicine

1

1

292

5

Immunology

1

1

26

Frederick Millard

×

29

Publications

1.8K

Citations

19

H-Index

YearCitations

Platelet-associated and plasma anti-glycoprotein autoantibodies in chronic ITP

Robert McMillan, P Tani, Frederick Millard,

Blood

1987

312

Adolescent and Young Adult Oncology, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

Peter F. Coccia, Alberto S. Pappo, Lynda K. Beaupin,

Journal of the National Comprehensive Cancer Network

2018

292

Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma

Matthew I. Milowsky, Christian Dittrich, Ignacio Durán,

European Journal of Cancer

2014

111

Feasibility and efficacy of neoadjuvant sunitinib before nephron‐sparing surgery

Jonathan Silberstein, Frederick Millard, Reza Mehrazin,

British Journal of Urology

2010

104

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B

Hedy L. Kindler, Frederick Millard, James E. Herndon,

Lung Cancer

2001

101

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Daniel F. Hayes, Hideko Yamauchi, Gloria Broadwater,

PubMed

2001

96

Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)

Stuart M. Lichtman, Donna Hollis, Antonius A. Miller,

Journal of Clinical Oncology

2006

91

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu,

Clinical Cancer Research

2016

77

Clinical manifestations of essential thrombocythemia in young adults

Frederick Millard, Christine S. Hunter, Michael Anderson,

American Journal of Hematology

1990

69

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

Russell K. Pachynski, Chihiro Morishima, Russell Z. Szmulewitz,

Journal for ImmunoTherapy of Cancer

2021

62

Page 1